Martigues

Malignant hypertension is a very severe type of high blood pressure that can be fatal if not treated. It mainly affects younger adults aged 35 to 55 and carries a high risk of serious heart and kidney problems. Despite its severity and increasing cases, research on malignant hypertension is limited, with diagnostic criteria and treatment guidelines that have not changed since 1929. This study aims to create the first prospective, multicenter registry to better understand the disease's epidemiology, care practices, and biological aspects, and to modernize its definition and diagnosis. The study plans to enroll 500 patients diagnosed with malignant hypertension based on classic criteria, including severe high blood pressure above 180/110 mmHg and evidence of organ damage. It will collect detailed data on patient characteristics, affected organs, and treatment approaches used in various centers. This registry will help develop new diagnostic and treatment recommendations based on solid scientific evidence and may lead to future therapeutic trials. Participants will be followed to evaluate their health outcomes over five years, focusing on their cardiovascular and renal prognosis. Researchers will analyze how patient profiles and the number and type of organ damage affect their long-term outlook. The study will document epidemiology, care pathways, organ involvement, and management strategies in detail to improve understanding and care of malignant hypertension.

Hidradenitis Suppurativa (HS) is a skin condition causing deep, painful bumps that appear where skin rubs together. These bumps can swell, become red, and sometimes fill with pus, turning into abscesses that may burst. Over time, HS can lead to scars and tunnels on or under the skin. This study aims to evaluate how safe and effective the drug zasocitinib is for adults with moderate to severe HS, comparing it to a placebo in a Phase 2 trial. Participants will receive either zasocitinib or a placebo capsule daily for 16 weeks. The placebo looks the same but contains no medicine. After this initial 4-month period, all participants, including those who first received placebo, will be offered zasocitinib for up to an additional 8 months. Throughout the study, participants will visit the clinic 12 times for treatment and monitoring. During the visits, researchers will assess treatment response, including the percentage of participants achieving a 75% reduction in HS signs at week 16. They will also monitor safety and tolerance of the medication. Participants will undergo various evaluations such as physical exams, lab tests, and questionnaires to track disease progress and side effects. The study includes careful follow-up to ensure participant safety and to gather detailed information on the drug's effects over the total study duration of up to 12 months.

Vitiligo is a long-term autoimmune condition where the immune system mistakenly attacks skin cells that produce pigment, leading to patches of skin that lose color. This study focuses on adults with nonsegmental vitiligo, where symmetrical patches of depigmentation appear on both sides of the body. The trial aims to evaluate the safety, effectiveness, and tolerability of zasocitinib in treating this condition in adults aged 18 to 75 years. Participants will receive either zasocitinib capsules or placebo capsules that look identical but contain no medicine. The treatment period lasts up to one year (52 weeks). Those initially receiving placebo will switch to zasocitinib after about six months. During the study, participants will visit the clinic 11 times for treatment and monitoring. Throughout the trial, researchers will assess how well participants respond to treatment by measuring improvement in facial vitiligo using a standardized scoring index at baseline and after 24 weeks. Additional evaluations include safety monitoring and adherence to the study procedures. Participants will undergo clinical assessments, laboratory tests, and provide informed consent before starting the trial.

Hidradenitis suppurativa (HS) is a chronic and often painful skin disease that causes lumps, abscesses, and scars in areas like under the breasts, armpits, inner thighs, groin, and buttocks. Researchers are evaluating the investigational drug lutikizumab compared to placebo in adults and adolescents with moderate to severe HS. This study aims to assess the disease activity and safety of lutikizumab in a Phase 3 clinical trial involving about 1280 participants worldwide.

This research aims to evaluate the effects of povorcitinib on reducing itch and improving skin lesions in adults with prurigo nodularis, a chronic skin condition characterized by itchy nodules. The study is a Phase 3 trial designed to assess the safety and efficacy of this treatment compared to a placebo in participants aged 18 to 75 years with a confirmed diagnosis of prurigo nodularis lasting at least three months. Participants will receive either oral povorcitinib tablets or placebo tablets as part of the randomized, double-blind study. Key eligibility includes having significant itch severity and at least 20 pruriginous lesions on multiple body regions. The study monitors the treatment effects over 24 weeks, focusing on improvements in itch intensity and skin lesion severity. During the study, participants will be closely monitored for changes in their itch scores and skin condition. Researchers will assess the proportion of participants achieving specified improvements by Week 24. Safety and tolerability will also be evaluated throughout the trial. Participants will undergo regular assessments including clinical evaluations, laboratory tests, and adherence monitoring to track progress and any side effects over the course of the study.

Researchers are evaluating the safety and effects of Abrocitinib, a medication given as a tablet once daily, for adults with moderate to severe atopic dermatitis (AD), a long-lasting skin condition causing inflammation, redness, and irritation. This observational cohort study aims to understand how Abrocitinib works in real-life clinical settings and its impact on patients with moderate-to-severe chronic AD who are eligible to receive this treatment. All participants will receive Abrocitinib daily and may continue using medicated topical treatments for their AD at the same time. The study lasts for 24 months, during which participants will visit the study clinic approximately five times, or about once every four to six months. These visits will allow researchers to monitor the effects and safety of the treatment in a real-world context. Participants will be closely observed for changes in their AD severity, specifically looking for improvements measured by the Investigator's Global Assessment (IGA) score at 16 weeks. The study will also assess safety and how patients manage their treatment over time. Overall, the study aims to provide valuable information on how Abrocitinib affects adults with moderate-to-severe atopic dermatitis in everyday clinical practice.

Researchers are studying the management and follow-up of non-muscle-invasive bladder cancer (NMIBC), a type of bladder tumor that affects the inner lining and underlying tissue but not the muscle layer. This cancer type accounts for a significant portion of bladder cancer cases in France, with many patients experiencing tumor recurrence within five years. The study aims to evaluate the diagnostic accuracy of urine biomarker tests compared to bladder endoscopy, which is the current standard for detecting tumor recurrence. Additionally, it will describe tumor characteristics, patient history, treatments, and regional differences in care. Patients being monitored for NMIBC and undergoing routine care will have their medical details, including prior treatments and urine test results, recorded in a registry. Follow-up includes regular bladder endoscopy exams, with dates and findings noted by urologists. Urine test results taken before biopsies will also be tracked. This observational study will analyze the performance of urine tests by calculating sensitivity, specificity, and predictive values, and exploring differences based on tumor grade, stage, and previous treatments. The goal is to include 8000 patients across France over six years. Participants will provide data through medical records and routine exams during their personalized care plans. Urine samples and bladder fibroscopy results will be collected at each follow-up visit to assess test accuracy over a five-year period. Researchers will monitor recurrence-free survival and urine test performance, aiming to identify if urine tests can safely reduce the need for invasive cystoscopy. The study focuses on long-term monitoring to better understand and improve care for NMIBC patients.

Post-thrombotic syndrome (PTS) is a frequent long-term complication of deep vein thrombosis (DVT) that significantly affects patients' quality of life and increases healthcare costs. This research aims to study how the extent of blood clot burden in the veins, measured by a special ultrasound score called the Venous Volumetric Index (VVI), can predict the likelihood and severity of PTS six months after a first episode of symptomatic DVT in the lower limbs. Understanding these predictive factors could help guide better treatment strategies for patients at risk of developing PTS. The study is a multicenter prospective cohort design involving patients diagnosed with a first episode of symptomatic lower limb DVT confirmed by ultrasound. Participants will be followed with clinical assessments and ultrasound scans at one week (only for those in biological research), one month, three months, and six months after diagnosis. Blood samples will be collected at baseline, one week, one month, and three months to examine inflammation and blood clotting factors. Quality of life questionnaires will be completed at three and six months. The VVI score will be calculated from ultrasound data to quantify the clot burden, and the Villalta scale will be used to assess PTS severity over the six-month follow-up period. During each visit, symptoms and clinical signs related to PTS will be evaluated, and color Doppler ultrasound of the lower limbs will be performed. Blood tests will help explore biological markers linked to PTS development. Patients will complete questionnaires about their quality of life to assess the impact of symptoms. The study concludes with the six-month visit, at which point researchers will analyze the association between initial clot burden and PTS outcomes. This comprehensive follow-up aims to improve the prediction and understanding of PTS after DVT.

Psoriasis is a chronic inflammatory disease influenced by genetic and environmental factors, with many patients experiencing recurring flares after an initial trigger. This research aims to compare the effectiveness of bimekizumab, an investigational drug, versus topical corticosteroids in controlling psoriasis symptoms, focusing on clinical disease activity at weeks 16 and 24. The study is a Phase 2, multicenter interventional trial involving adults with mild plaque psoriasis. Participants will be randomly assigned to receive either 320 mg of bimekizumab at weeks 0, 4, 8, and 12, or clobetasol ointment applied once daily in the evening for up to 4 weeks until lesions clear. Afterward, clobetasol will be applied twice weekly until week 16, then stopped. No active treatment is given between weeks 16 and 24. From week 24 to 96, patients experiencing flares may use continuous topical clobetasol as needed but will be considered non-responders for analysis. If psoriasis worsens to moderate or severe, participants will end the study and be referred for standard care. Throughout the study, patients will undergo assessments and sample collections to monitor psoriasis activity and treatment response. Researchers will measure psoriasis severity using clinical scores and evaluate safety. Patients must attend all study visits over the planned period to ensure thorough monitoring of treatment effects and disease progression.

Benign prostatic hyperplasia (BPH), also called prostate adenoma, is a common non-cancerous growth of the prostate that mainly affects men over 40, with risk increasing significantly after age 50. This condition causes lower urinary tract symptoms (LUTS) such as difficulty starting urination, feeling of incomplete bladder emptying, frequent urination especially at night, and reduced urine flow. High-intensity focused ultrasound (HIFU) is a technique that uses targeted heat to destroy tissue precisely without invasive surgery, and it has been used in prostate cancer treatment. This study aims to evaluate the safety and effectiveness of HIFU specifically for treating BPH by reducing prostate volume and improving urinary symptoms. Participants will receive HIFU treatment, which delivers focused ultrasound waves endorectally to create localized necrosis of the prostate side lobes. This targeted destruction is intended to shrink the prostatic transition zone, relieving pressure on the urethra. The study includes follow-ups at 3, 6, 12, 18, and 36 months to assess outcomes. No invasive surgery or radiation is involved, and treatment monitoring is done in real time. During the study, participants will be monitored for adverse events and improvements in urinary flow and symptom scores. Evaluations include measuring urine flow rate (Qmax), symptom severity (IPSS), quality of life related to urinary symptoms (IPSS-QoL), and imaging by MRI to observe prostate changes. Safety and symptom improvement will be tracked over months, with primary outcomes assessed at 3 and 6 months. Participants are involved in completing questionnaires and undergoing imaging and clinical assessments throughout the study duration.